The medication is now contraindicated in patients with cardiac conditions and taking certain antiarrhythmic medications. Patients beginning therapy will also undergo an observation period with cardiovascular monitoring. How will you change the counseling information you provide to patients beginning this treatment?

http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm

Advertisements